547 related articles for article (PubMed ID: 8669822)
1. Effect of progestin treatment on estradiol-and growth factor-stimulated breast cancer cell lines.
Cappelletti V; Miodini P; Fioravanti L; Di Fronzo G
Anticancer Res; 1995; 15(6B):2551-5. PubMed ID: 8669822
[TBL] [Abstract][Full Text] [Related]
2. Progestin regulation of vascular endothelial growth factor in human breast cancer cells.
Hyder SM; Murthy L; Stancel GM
Cancer Res; 1998 Feb; 58(3):392-5. PubMed ID: 9458078
[TBL] [Abstract][Full Text] [Related]
3. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol.
Karey KP; Sirbasku DA
Cancer Res; 1988 Jul; 48(14):4083-92. PubMed ID: 3289739
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factors modulate the growth inhibitory effects of retinoic acid on MCF-7 breast cancer cells.
Bentel JM; Lebwohl DE; Cullen KJ; Rubin MS; Rosen N; Mendelsohn J; Miller WH
J Cell Physiol; 1995 Oct; 165(1):212-21. PubMed ID: 7559803
[TBL] [Abstract][Full Text] [Related]
5. The effect of progesterone and synthetic progestins on serum- and estradiol-stimulated proliferation of human breast cancer cells.
Seeger H; Wallwiener D; Mueck AO
Horm Metab Res; 2003 Feb; 35(2):76-80. PubMed ID: 12734785
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms involved in the evolution of progestin resistance in human breast cancer cells.
Murphy LC; Dotzlaw H; Wong MS; Miller T; Murphy LJ
Cancer Res; 1991 Apr; 51(8):2051-7. PubMed ID: 1849041
[TBL] [Abstract][Full Text] [Related]
7. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition.
Mueck AO; Seeger H; Wallwiener D
Climacteric; 2003 Sep; 6(3):221-7. PubMed ID: 14567770
[TBL] [Abstract][Full Text] [Related]
9. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
Milewicz T; Kolodziejczyk J; Krzysiek J; Basta A; Sztefko K; Kurek S; Stachura J; Gregoraszczuk EL
Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
[TBL] [Abstract][Full Text] [Related]
10. Alterations in transforming growth factor-alpha and -beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth.
Herman ME; Katzenellenbogen BS
Cancer Res; 1994 Nov; 54(22):5867-74. PubMed ID: 7954416
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine.
Strobl JS; Kirkwood KL; Lantz TK; Lewine MA; Peterson VA; Worley JF
Cancer Res; 1990 Sep; 50(17):5399-405. PubMed ID: 2386945
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the growth-inhibitory effects of progestins and the antiestrogen hydroxyclomiphene on human breast cancer cells by epidermal growth factor and insulin.
Koga M; Musgrove EA; Sutherland RL
Cancer Res; 1989 Jan; 49(1):112-6. PubMed ID: 2642286
[TBL] [Abstract][Full Text] [Related]
13. Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins.
Lanari C; Lüthy I; Lamb CA; Fabris V; Pagano E; Helguero LA; Sanjuan N; Merani S; Molinolo AA
Cancer Res; 2001 Jan; 61(1):293-302. PubMed ID: 11196177
[TBL] [Abstract][Full Text] [Related]
14. Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis.
Seeger H; Wallwiener D; Mueck AO
Gynecol Endocrinol; 2008 Oct; 24(10):576-9. PubMed ID: 19012101
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors.
Bakker GH; Setyono-Han B; Henkelman MS; de Jong FH; Lamberts SW; van der Schoot P; Klijn JG
Cancer Treat Rep; 1987 Nov; 71(11):1021-7. PubMed ID: 3119199
[TBL] [Abstract][Full Text] [Related]
16. Changes in protein tyrosine phosphatase type IVA member 1 and zinc finger protein 36 C3H type-like 1 expression demonstrate altered estrogen and progestin effect in medroxyprogesterone acetate-resistant and estrogen-independent breast cancer cell models.
Pennanen PT; Sarvilinna NS; Purmonen SR; Ylikomi TJ
Steroids; 2009; 74(4-5):404-9. PubMed ID: 19146866
[TBL] [Abstract][Full Text] [Related]
17. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells.
Sutherland RL; Hall RE; Pang GY; Musgrove EA; Clarke CL
Cancer Res; 1988 Sep; 48(18):5084-91. PubMed ID: 2970295
[TBL] [Abstract][Full Text] [Related]
18. Growth control of human mammary cancer cells (MCF-7 cells) in culture: effect of estradiol and growth factors in serum-containing medium.
Aakvaag A; Utaaker E; Thorsen T; Lea OA; Lahooti H
Cancer Res; 1990 Dec; 50(24):7806-10. PubMed ID: 2253223
[TBL] [Abstract][Full Text] [Related]
19. Effects of progestins of human proliferative endometrium: an in vitro model of potential clinical relevance.
Illouz S; Dales JP; Sferlazzo K; Garcia S; Carpentier-Meunier S; Boubli L; Lavaut MN; Charpin C
Int J Mol Med; 2003 Oct; 12(4):517-23. PubMed ID: 12964029
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibition and increase of insulin receptors in antiestrogen-resistant T47DCO human breast cancer cells by progestins: implications for endocrine therapies.
Horwitz KB; Freidenberg GR
Cancer Res; 1985 Jan; 45(1):167-73. PubMed ID: 3838085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
